Access cutting-edge advanced unresectable hepatocellular carcinoma treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Dallas location
Preparing your pre-screening questions…
Access advanced unresectable hepatocellular carcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced unresectable hepatocellular carcinoma treatment provided free
Check if you qualify for this advanced unresectable hepatocellular carcinoma clinical trial in Dallas, TX
No-Cost Study Care
Local to Dallas
Convenient for TX residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.
Sponsor: Riboscience, LLC.
Yes, this clinical trial (NCT07175441) has an active research site in Dallas, TX that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for advanced unresectable hepatocellular carcinoma treatment options in Dallas, TX, this clinical trial (NCT07175441) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced unresectable hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all advanced unresectable hepatocellular carcinoma clinical trials near you to find additional studies recruiting in your area.
See all liver cancer clinical trials recruiting in Dallas — not just this study.
Browse Liver Cancer Trials in Dallas →